Ipsen's US-based subsidiary, Biomeasure, and its North American Operations group announced that it will further expand its commitment, investment and commercial presence in the US market. Ipsen will make a multi-million dollar capital investment in its Milford, MA research and development and technical operations facility, and will relocate US Operations headquarters from Brisbane, CA, to Bridgewater, NJ, in order to enhance the North American commercial organization.

The existing 77,000 square-foot Milford facility serves as a center for Ipsen's US-based peptide and toxin R&D platforms, as well as a cGMP manufacturing facility focused on production of recombinant proteins for the treatment of hemophilia.

The expansion and renovation capital investment project will deliver a new three-story, 62,000 square-foot building while completely renovating one of the site's two existing buildings. Ground breaking is anticipated for mid-2012, with construction of the new building targeted for completion in early 2014. The new facility will house R&D and process sciences laboratories that support Ipsen's strategic objectives to deliver five New Molecular Entities (NMEs) and three Proofs of Concept (POCs) by 2015.

Ipsen is also moving the headquarters of its US subsidiary to Bridgewater, NJ to a 30,000 square-foot facility, under a six-and-a-half-year lease.

"New Jersey is the leading biopharmaceutical center in the US, and Ipsen is ready and eager to be a part of that community of innovators," said Sean McKercher, president and general manager, Ipsen North America.

The company expects to hire more than 100 employees, including many members of its developing executive team, who will work from the Bridgewater, NJ location. The company expects to begin operation from the Bridgewater location by April 2012.